marginally significantp=0.088
In COPD patients, ICS use showed a marginally significant increased risk for narrowly defined IPF (adjusted HR: 3.00, 95% CI: 0.48 to 18.61, p=0.088), but not for broadly defined IPF.
In COPD patients, ICS use showed a marginally significant increased risk for narrowly defined IPF (adjusted HR: 3.00, 95% CI: 0.48 to 18.61, p=0.088), but not for broadly defined IPF.